Skip to main content
Vivian Wu, MD, Otolaryngology (ENT), Santa Monica, CA

Vivian Wu MD

Head & Neck Microvascular Surgery, Head & Neck Oncologic Surgery


Surgeon, Otolaryngology/Head & Neck Surgical Oncology

Join to View Full Profile
  • 1301 20th StSte 300Santa Monica, CA 90404

  • Phone+1 310-829-7792

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Vivian Wu is an Otolaryngologist in Los Angeles. She specializes in Head & Neck Oncologic Surgery. Her training includes a fellowship in Head & Neck Surgical Oncology at the University of Michigan Health System and a residency in Otolaryngology - Head and Neck Surgery at Oregon Health & Science University. She has also authored several well-cited publications in the fields of surgical pathology and oncology.

Education & Training

  • University of Michigan Health System
    University of Michigan Health SystemFellowship, Head & Neck Surgical Oncology/Microvascular Reconstruction, 2011 - 2013
  • Oregon Health & Science University (OHSU Health)
    Oregon Health & Science University (OHSU Health)Residency, Otolaryngology - Head and Neck Surgery, 2004 - 2011
  • Howard University College of Medicine
    Howard University College of MedicineClass of 2004

Certifications & Licensure

  • OR State Medical License
    OR State Medical License 2010 - Present
  • MI State Medical License
    MI State Medical License 2011 - 2027
  • CA State Medical License
    CA State Medical License 2024 - 2026
  • VA State Medical License
    VA State Medical License 2013 - 2018
  • Otolaryngology
    American Board of Otolaryngology - Head and Neck Surgery Otolaryngology

Publications & Presentations

PubMed

Press Mentions

  • Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 11th, 2020
  • Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin plus Nivolumab in 'Cancer Discovery' Journal
    Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin plus Nivolumab in 'Cancer Discovery' JournalMay 22nd, 2020
  • Hospitals Don’t Shift Costs from Medicare or Medicaid to Private Insurers
    Hospitals Don’t Shift Costs from Medicare or Medicaid to Private InsurersJune 8th, 2017

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: